Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 41
Summary
- Conditions
- Platinum-Resistant Primary Peritoneal Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Stage IVB Fallopian Tube Cancer AJCC v8
- Stage IIIA Fallopian Tube Cancer AJCC v8
- Platinum-Resistant Ovarian Carcinoma
- Stage IIIA1 Fallopian Tube Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIC Primary Peritoneal Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Recurrent Fallopian Tube Carcinoma
- Stage IVA Primary Peritoneal Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Primary Peritoneal Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Fallopian Tube Carcinoma
- Refractory Ovarian Carcinoma
- Stage IIIC Fallopian Tube Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Stage IVB Primary Peritoneal Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Refractory Primary Peritoneal Carcinoma
- Stage IIIA2 Fallopian Tube Cancer AJCC v8
- Stage IVA Fallopian Tube Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIB Fallopian Tube Cancer AJCC v8
- Stage IIIA Primary Peritoneal Cancer AJCC v8
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03907527
- Collaborators
- National Cancer Institute (NCI)
- Precigen, Inc
- Investigators
- Principal Investigator: John Liao Fred Hutch/University of Washington Cancer Consortium
Get Well Soon